Fibronostics at AASLD 2026: Connecting Through Science and Collaboration
Fibronostics will attend AASLD’s The Liver Meeting® 2026, taking place November 5–9, 2026, at the Colorado
Convention Center in Denver, Colorado.
Brock Smith, Dr Mona Munteanu, and David Cashio will represent Fibronostics, connecting with clinicians,
researchers, and partners to discuss advances in non-invasive liver assessment.
Two posters co-authored by Dr Mona Munteanu will feature research on identifying advanced fibrosis and
supporting treatment initiation and monitoring in MASLD/MASH.
Presenting: Sequential Testing for Advanced Fibrosis LIVERFASt™ in Sequential Combination with Vibration Controlled Transient Elastography (VCTE) Outperforms FIB-4 and VCTE for Identifying Advanced Fibrosis (≥F3) in Patients with MASLD
Presentation: Friday, November 6, 2026 | 1:00–2:00 p.m.
Session: Diagnostics and Biomarkers – MASH
Presentation: Non-Invasive Assessment in Resmetirom Therapy A Multimodal Noninvasive Approach to Initiation and Monitoring of Resmetirom Therapy in MASH – Update
Presentation: Saturday, November 7, 2026 | 1:00–2:00 p.m.
Session: MASLD/MASH – Therapeutics: New Agents and Approved/Available Agents
All presentation times are local to Denver.
Connect with Our Team
We look forward to sharing these studies, exchanging clinical perspectives, and exploring collaborations that
advance liver care.
Attending The Liver Meeting®? Connect with Brock, Dr Mona, and David, and join the poster sessions to learn more about the research.